Aims Obesity is common and associated with unique phenotypic features in heart failure
with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of …

Importance In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure
(DAPA-HF) trial, dapagliflozin was shown to reduce cardiovascular mortality and …

Background: Frailty is increasing in prevalence. Because patients with frailty are often
perceived to have a less favorable risk/benefit profile, they may be less likely to receive new …

Aim To estimate the cost‐effectiveness of dapagliflozin added to standard therapy, vs.
standard therapy only, in patients with heart failure (HF) with reduced ejection fraction …

Aim Anaemia is common in heart failure and associated with worse outcomes. We examined
the effect of dapagliflozin on correction of anaemia in patients with heart failure (HF) and …

Background Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces
cardiovascular death and worsening heart failure in patients with chronic heart failure and …